BlossomHill to present BH-30643 trial data at lung cancer conference
Tweet Send to a Friend
BlossomHill Therapeutics, Inc. (Nasdaq: BLSM) announced it will present updated data from its ongoing Phase 1/2 SOLARA trial of BH-30643 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
